The 2026 Medical Pharmacy Trend Report: Part 1– Payer Survey reflects Prime Therapeutics’ long standing commitment to delivering trusted, data driven perspectives that shape the industry...

Real-world data reveal a persistent challenge: helping patients maintain GLP-1 treatment long enough to realize its full benefits

Lassen, chief clinical officer at Prime Therapeutics/Magellan Rx, shares insights on GLP-1 weight-loss drugs and evidence-based approaches to providing the kind of care we’d want for our loved ones.

From new treatment options for dry eye disease to type 2 diabetes, here are a few of the top U.S. Food and Drug Administration drug decisions expected this year